Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewJHW 007 hydrochloride is a dopamine uptake inhibitor; displays high affinity for the dopamine transporter (DAT) (Ki = 25 nM compared to 1330 and 1730 for NET and SERT respectively). Suppresses the effects of cocaine administration in a dose-dependent manner and decreases cocaine and methamphetamine self-administration in rats.
JHW 007 hydrochloride is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
分子量 | 421.95 |
公式 | C24H29F2NO.HCl |
储存 | Store at -20°C |
纯度 | ≥99% (HPLC) |
CAS Number | 202645-74-7 |
PubChem ID | 71771746 |
InChI Key | RHYMGBAYGRUKNZ-DHWZJIOFSA-N |
Smiles | [H][C@@]12CC[C@@](C[C@H](OC(C4=CC=C(F)C=C4)C3=CC=C(F)C=C3)C2)([H])N1CCCC.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 42.19 | 100 | |
ethanol | 42.19 | 100 |
以下数据基于产品分子量 421.95。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.37 mL | 11.85 mL | 23.7 mL |
5 mM | 0.47 mL | 2.37 mL | 4.74 mL |
10 mM | 0.24 mL | 1.18 mL | 2.37 mL |
50 mM | 0.05 mL | 0.24 mL | 0.47 mL |
参考文献是支持产品生物活性的出版物。
Kristensen et al (2011) SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol.Rev. 63 585 PMID: 21752877
Kopajtic et al (2010) DA transporter-dependent and -independent striatal binding of the benztr. analog JHW 007, a cocaine antagonist with low abuse liability. J.Pharmacol.Exp.Ther. 335 703 PMID: 20855444
Velaquez-Sanchez et al (2010) The high affinity DA uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization. Eur.Neuropsychopharmacol. 20 501 PMID: 20413276
Hiranita et al (2014) Preclinical efficacy of N-substituted benztr. analogs as antagonists of metha. self-administration in rats. J.Pharmacol.Exp.Ther. 348 174 PMID: 24194527
If you know of a relevant reference for JHW 007 hydrochloride, please let us know.
关键词: JHW 007 hydrochloride, JHW 007 hydrochloride supplier, JHW007, dopamine, uptake, inhibitors, inhibits, DAT, transporter, Dopamine, Transporters, 4351, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 JHW 007 hydrochloride 的部分引用包括:
Andersen et al (2015) Binding site residues control inhibitor selectivity in the human NE transporter but not in the human DA transporter. Stem Cell Reports 5 15650 PMID: 26503701
您是否知道使用了 Tocris JHW 007 hydrochloride 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review JHW 007 hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.